Dechra Pharmaceuticals

From Wikipedia, the free encyclopedia
Jump to navigation Jump to search

Dechra Pharmaceuticals PLC
Traded asLSEDPH
Key people
Tony Rice, (Chairman)
Ian Page, (CEO)
Revenue£481.8 million (2019)[1]
£127.4 million (2019)[1]
£30.9 million (2019)[1]

Dechra Pharmaceuticals PLC is an England-based business involved in the development and marketing of veterinary products. It is listed on the London Stock Exchange and is a constituent of the FTSE 250 Index.


The Company was founded in 1997 by way of a management buy-out from Lloyds Chemists.[2] It was first listed on the London Stock Exchange in 2000.[2] In 2007 it bought VetXX, a Danish veterinary products business, for £62 million.[3] In 2010 it based Florida-based DermaPet for US$64 million[4] and Sussex-based Genitrix for £5 million.[5]

It sold its veterinary services business to US-firm, Patterson Companies, for £87.5m in July 2013 in order to focus on its higher margin manufacturing business.[6]


The Company sells pharmaceuticals - mainly for dogs, cats, equine and food producing animals; products include Vetoryl for Cushing's disease in dogs and Felimazole for hyperthyroidism in cats. It is organised into two divisions: European Pharmaceuticals and US Pharmaceuticals.[7]

See also[edit]


  1. ^ a b c "Annual Report 2019". Dechra Pharmaceuticals. Retrieved 1 March 2020.
  2. ^ a b Montague Private Equity announces sale of VetXX
  3. ^ "Dechra Pharma to buy VetXX for 61.7 mln stg". Reuters. Retrieved 28 March 2015.
  4. ^ "Dechra Pharma buys DermaPet for US$64 mln". Proactive Investors. 22 October 2010. Retrieved 1 March 2020.
  5. ^ "Dechra acquires Sussex-based Genitrix in a £5.4m deal". Business Live. 1 December 2010. Retrieved 1 March 2020.
  6. ^ "Dechra sells up". Investors Chronicle. 11 July 2013. Retrieved 16 March 2014.
  7. ^ "Dechra Pharmaceuticals PLC". Retrieved 28 March 2015.